Novo Nordisk A/S (NYSE:NVO) Trading 1% Higher – Here’s Why

Novo Nordisk A/S (NYSE:NVO) shares were up 1% on Friday . The company traded as high as $48.80 and last traded at $48.0990. Approximately 10,599,786 shares changed hands during mid-day trading, a decline of 19% from the average daily volume of 13,092,534 shares. The stock had previously closed at $47.61.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo filed an NDA with the U.S. FDA for once?weekly CagriSema, a next?generation combination obesity injection that showed superior Phase III weight?loss results — a potential major booster to its obesity franchise if approved. Article Title
• Positive Sentiment: Novo is pursuing a higher 7.2 mg Wegovy dose after data showed stronger weight loss — this could help reclaim share versus rivals (e.g., Eli Lilly’s Zepbound) if approved and commercialized effectively. Article Title
• Positive Sentiment: Analyst/commentary pieces highlight upside from oral Wegovy development, supply?chain fixes and restructuring that could materially improve margins and growth if execution continues. Article Title
• Positive Sentiment: Kepler Capital initiated/maintained a buy view (reported coverage), giving some buy?side support to the shares. Article Title
• Neutral Sentiment: UBS reiterated a Neutral (Hold) rating and left its price target unchanged, signaling continued caution on competitive pressures despite product progress. Article Title
• Neutral Sentiment: Commentary pieces are reassessing Novo’s valuation after a steep, year?long share decline; some see a longer runway to recovery while others point to durable competitive threats. Article Title
• Negative Sentiment: Novo issued profit warnings and underwent a CEO change earlier this year and cut guidance, contributing to a large YTD share decline; that operational uncertainty remains a drag on investor confidence. Article Title
• Negative Sentiment: Shares recently dipped more than the broader market after earnings/profitability concerns were flagged; short?term volatility is likely to persist as investors weigh approvals vs competitive share losses. Article Title

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NVO shares. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. Finally, BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a research note on Tuesday, November 25th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Stock Performance

The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock’s 50 day moving average price is $50.01 and its two-hundred day moving average price is $57.86. The firm has a market capitalization of $214.76 billion, a PE ratio of 13.98 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The firm had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Academy Capital Management grew its holdings in shares of Novo Nordisk A/S by 0.3% during the third quarter. Academy Capital Management now owns 367,419 shares of the company’s stock worth $20,388,000 after buying an additional 1,170 shares in the last quarter. IFP Advisors Inc boosted its position in Novo Nordisk A/S by 21.1% during the third quarter. IFP Advisors Inc now owns 13,712 shares of the company’s stock worth $761,000 after acquiring an additional 2,391 shares during the last quarter. Innova Wealth Partners grew its stake in Novo Nordisk A/S by 35.6% in the 3rd quarter. Innova Wealth Partners now owns 4,091 shares of the company’s stock worth $227,000 after acquiring an additional 1,073 shares during the period. Tevis Investment Management grew its stake in Novo Nordisk A/S by 12.1% in the 3rd quarter. Tevis Investment Management now owns 44,700 shares of the company’s stock worth $2,480,000 after acquiring an additional 4,838 shares during the period. Finally, XXEC Inc. raised its holdings in Novo Nordisk A/S by 26.7% in the 3rd quarter. XXEC Inc. now owns 99,075 shares of the company’s stock valued at $5,498,000 after acquiring an additional 20,890 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.